Microbot Medical Confirms GLP Pre-Clinical Trial is on Track to Commence Later this Month

Rhea-AI Summary

Microbot Medical (NASDAQ: MBOT) has shipped multiple LIBERTY Robotic System devices for a GLP pre-clinical trial, scheduled to start this month, at a leading research laboratory. This initiative is part of the company's preparations for FDA and CE Mark submissions. CEO Harel Gadot expressed optimism about their collaboration with top experts, indicating that the trial results will validate prior successful animal studies.

Positive

• Commencement of GLP pre-clinical trial for the LIBERTY Robotic System is a significant step toward regulatory submissions.
• Collaboration with a leading research institute and key opinion leaders may enhance the credibility of trial outcomes.

Negative

• The reliance on trial outcomes introduces uncertainty regarding the commercial viability of the LIBERTY Robotic System.
• Risks related to regulatory approvals and the development timeline may affect investor confidence.

HINGHAM, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced, as part of the preparation for its anticipated U.S. Food and Drug Administration (FDA) and CE Mark submissions, that it recently shipped multiple LIBERTY Robotic System devices to a market-leading research laboratory to conduct the Company’s GLP pre-clinical trial. The comprehensive trial, which is anticipated to commence later this month, will be performed by a team of global leaders in the endovascular space at a state-of-the-art lab with FDA approved levels of planning, controlling, monitoring and reporting (GLP standards).

“We are very excited to commence the first step of our regulatory process leading to the anticipated clearances for our LIBERTY® Robotic system,” commented Harel Gadot, Chairman, CEO and President. “We are confident the collaboration with a world-leading research institute, coupled with the Key Opinion Leaders performing the study, will allow us to progress as planned.”

The Company expects the results of the GLP pre-clinical trial will further validate the successful outcomes from multiple prior animal feasibility studies performed.

About Microbot Medical Inc.

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements as to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct the SCS’s EFS which could adversely affect or delay the EFS, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michael Polyviou
EVC Group
mpolyviou@evcgroup.com
732-933-2754

FAQ

What is the purpose of Microbot Medical's GLP pre-clinical trial?

The trial aims to validate the LIBERTY Robotic System's effectiveness and support future FDA and CE Mark submissions.

When is the GLP pre-clinical trial expected to start?

The trial is anticipated to commence later this month.

What are the expected outcomes of the GLP pre-clinical trial for MBOT?

The trial results are expected to confirm successful outcomes from previous animal studies.

How does the GLP pre-clinical trial impact MBOT's stock performance?

Successful trial results could positively influence future regulatory approvals and market perception, affecting stock performance.